Boston Scientific Corporation
BSX · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $131,434,380 | $83,997,930 | $66,189,235 | $60,419,304 |
| - Cash | $414,000 | $865,000 | $928,000 | $1,925,000 |
| + Debt | $11,147,000 | $9,492,000 | $9,282,000 | $9,451,000 |
| Enterprise Value | $142,167,380 | $92,624,930 | $74,543,235 | $67,945,304 |
| Revenue | $16,747,000 | $14,240,000 | $12,682,000 | $11,888,000 |
| % Growth | 17.6% | 12.3% | 6.7% | – |
| Gross Profit | $10,267,000 | $8,831,000 | $7,714,000 | $7,461,000 |
| % Margin | 61.3% | 62% | 60.8% | 62.8% |
| EBITDA | $3,938,000 | $3,453,000 | $2,741,000 | $2,518,000 |
| % Margin | 23.5% | 24.2% | 21.6% | 21.2% |
| Net Income | $1,854,000 | $1,593,000 | $698,000 | $1,040,000 |
| % Margin | 11.1% | 11.2% | 5.5% | 8.7% |
| EPS Diluted | 1.25 | 1.073 | 0.446 | 0.687 |
| % Growth | 16.5% | 140.6% | -35.1% | – |
| Operating Cash Flow | $3,435,000 | $2,503,000 | $1,526,000 | $1,870,000 |
| Capital Expenditures | -$790,000 | -$800,000 | -$612,000 | -$554,000 |
| Free Cash Flow | $2,645,000 | $1,703,000 | $914,000 | $1,316,000 |